ABSTRACT
BACKGROUND: Ultrasound (US)-guided transversus abdominis plane (TAP) block is widely-spread analgesic technique for the patients undergoing abdominal surgery and can be provided safely for the patients receiving anticoagulation therapy. We conducted a retrospective comparative trial of analgesic efficacy between the patient who received US-guided TAP block with postoperative continuous iv-fentanyl infusion (group T) and those who received epidural analgesia (group E). METHODS: Twenty three patients who had undergone abdominal aortic replacement were analyzed retrospectively. The number of patients in group T was 12, and those in group E was 11. The postoperative first ambulation day, the postoperative first oral feeding day, the length of hospital stay, the use of rescue analgesic medication, and the incidence of postoperative nausea and vomiting (PONV) were compared between the two groups. P<0.05 was considered significant RESULTS: There were no significant differences in baseline characteristics between the two groups. There were no significant differences in postoperative first ambulation day (P=0.97), the postoperative first oral feeding day (P=0.46), the length of hospital stay (P= 0.32), the number of times of rescue analgesic medication (P=0.55), and the incidence of PONV between the two groups. CONCLUSIONS: US-guided TAP block is a useful option as analgesic technique for patients undergoing abdominal aortic replacement
Subject(s)
Abdominal Muscles/innervation , Abdominal Muscles/ultrastructure , Analgesia, Epidural , Aorta, Abdominal/surgery , Aortic Aneurysm, Abdominal/surgery , Blood Vessel Prosthesis Implantation , Fentanyl/administration & dosage , Nerve Block/methods , Pain, Postoperative/prevention & control , Aged , Aged, 80 and over , Female , Humans , Incidence , Infusions, Intravenous , Male , Middle Aged , Postoperative Nausea and Vomiting/epidemiology , Retrospective Studies , Treatment OutcomeABSTRACT
Rebamipide, a cytoprotective agent, has been suspected to attenuate oral mucositis through anti-inflammatory potentials and induction of endogenous prostaglandin synthesis. This prospective study was designed to assess the clinical efficacy of rebamipide gargle against oral mucositis, which is induced by fluoropyrimidines in patients with stomach and colorectal cancer. We first conducted a pilot study on gargle flavors, because the solution in this agent has a strong and bitter after taste. Nine kinds of flavors were prepared, and six characteristics were evaluated by ten volunteers: sourness, bitterness, sweetness, remain, after taste, and hard to drink. We determined the contents of rebamipide using HPLC, which showed stability in an acidic condition. Finally, we decided that 100% Pokka Lemon should be used as the flavor of the rebamipide solution. A clinical study was then started to compare the preventive effects rebamipide gargle and placebo have on stomatitis, quality of life (QOL), and the therapeutic effects of chemotherapy.
